Sel-1L Antibody (F-3): sc-377350

Sel-1L Antibody (F-3) is a mouse monoclonal IgG1 kappa light chain antibody that detects Sel-1L protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). anti-Sel-1L antibody (F-3) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Sel-1L protein is primarily located in cytoplasm and nuclei of normal pancreatic cells, which is significant as localization is crucial for cellular signaling and tumor suppression roles. Sel-1L has been shown to possess antiproliferative properties, effectively inhibiting tumor cell growth in various cancers, including breast, pancreatic, esophageal, and prostate cancers. This inhibition occurs through extracellular matrix remodeling, creating a microenvironment less conducive to invasive growth. Sel-1L may influence transforming growth factor-beta signaling pathways, which are vital for regulating cell growth and differentiation. Approximately two-thirds of breast tumors exhibit marked downregulation or complete absence of Sel-1L expression, leading to disrupted cell-matrix interactions and collagen binding. This disruption facilitates transition from normal mucosa to neoplastic lesions, suggesting Sel-1L could serve as a potential biomarker for identifying patients at high risk of developing cancer.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Sel-1L Antibody (F-3) References:

1. SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro.  |  Orlandi, R., et al. 2002. Cancer Res. 62: 567-74. PMID: 11809711
2. Identification of a region within SEL1L protein required for tumour growth inhibition.  |  Cattaneo, M., et al. 2004. Gene. 326: 149-56. PMID: 14729273
3. RNA-mediated interference indicates that SEL1L plays a role in pancreatic beta-cell growth.  |  Diaferia, G., et al. 2004. DNA Cell Biol. 23: 510-8. PMID: 15307954
4. SEL1L and squamous cell carcinoma of the esophagus.  |  Granelli, P., et al. 2004. Clin Cancer Res. 10: 5857-61. PMID: 15355917
5. Identification of a novel polymorphism in the fibronectin type II domain of the SEL1L gene and possible relation to the persistent hyperinsulinemic hypoglycemia of infancy.  |  Saltini, G., et al. 2004. Mutat Res. 554: 159-63. PMID: 15450414
6. Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction.  |  Bianchi, L., et al. 2005. Proteomics. 5: 2433-42. PMID: 15880780
7. SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactions.  |  Cattaneo, M., et al. 2005. Neoplasia. 7: 1030-8. PMID: 16331889
8. SEL1L expression in non-small cell lung cancer.  |  Ferrero, S., et al. 2006. Hum Pathol. 37: 505-12. PMID: 16647946
9. SEL1L-HRD1 endoplasmic reticulum-associated degradation controls STING-mediated innate immunity by limiting the size of the activable STING pool.  |  Ji, Y., et al. 2023. Nat Cell Biol. 25: 726-739. PMID: 37142791
10. SEL1L preserves CD8+ T-cell survival and homeostasis by fine-tuning PERK signaling and the IL-15 receptor-mediated mTORC1 axis.  |  Gao, Y., et al. 2023. Cell Mol Immunol. 20: 1232-1250. PMID: 37644166
11. SEL1L-HRD1 interaction is required to form a functional HRD1 ERAD complex.  |  Lin, LL., et al. 2024. Nat Commun. 15: 1440. PMID: 38365914
12. Regulation of hepatic inclusions and fibrinogen biogenesis by SEL1L-HRD1 ERAD.  |  Song, Z., et al. 2024. Nat Commun. 15: 9244. PMID: 39455574

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Sel-1L Antibody (F-3) has 7 citations in a variety of scientific publications.

Primary antibodies like Anti-Sel-1L Antibody (F-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Sel-1L Antibody (F-3) Specifications

Alternate Product Name: Sel-1L

Product Clone Name: F-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 417-473

Epitope Target: Sel-1L

Epitope Species: human

Product Reactivity/Detection: Sel-1L

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 7 citations in various scientific publications

Available Conjugates/Forms for Sel-1L Antibody (F-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin